ARCHIVES

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

MET Inhibitor Improved Time To Progression by 56 Percent

June 29, 2012

In Brief: FASEB Recommends $11.75 Billion NIH Budget; Natcher Wins House Appropriations Chairmanship

December 11, 1992

Surgery Lowers Risk By 90% In Women With Gene Mutations

April 30, 2004

NCI Plans $175 Million In Program Cuts To Cover Deficit, Fund New Initiatives

November 17, 2006

Biostatistician Thomas Fleming Warns Against Approval of Provenge.

May 4, 2007

Drug Development: Herceptin Associated with 15 Deaths, Genentech Says

May 12, 2000